Lv0
0 积分 2022-09-22 加入
Demographic and Geographic Trends in Myasthenia Gravis-Related Mortality in the United States, 1999-2022
1天前
待确认
Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience
7天前
已完结
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions
20天前
已完结
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension
20天前
已完结
Sustained Minimal Manifestations With Extended Interval Dosing of Efgartigimod in Seronegative Myasthenia Gravis: Case Report
21天前
已完结
Peripheral immune profiling highlights a dynamic role of low-density granulocytes in myasthenia gravis
21天前
已完结
Light Sensitivity in Myasthenia Gravis: Clinical Characteristics and Impact on Quality of Life
21天前
已完结
Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases
29天前
已完结
Statin‑associated myasthenia gravis: a real-world retrospective and pharmacovigilance study
29天前
已完结
Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series
30天前
已完结
皖公网安备34019202002308
